MedTrace Logo

Study of PI-88 in Patients With Advanced Melanoma

NCT00068172 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2022-06-27

No results posted yet for this study

Summary

The purpose of this study is to determine whether PI-88 is safe and effective in the treatment of advanced melanoma.

Conditions

Interventions

DRUG

PI-88

Sponsors & Collaborators

  • Medigen Biotechnology Corporation

    collaborator INDUSTRY

  • Cellxpert Biotechnology Corp.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-07-31
Primary Completion
2007-06-30
Completion
2007-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00068172 on ClinicalTrials.gov